Nutrients · Nov 14, 2026
Targeted Micronutritional Support in Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Prospective, Single-Arm Pilot Study of Hepatic Steatosis and Cardiometabolic Outcomes
By Argemí Relat M, Abanades S, San Mauro I et al.
Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) involves insulin resistance, altered iron homeostasis, and oxidative stress. We explored changes in hepatic steatosis and cardiometabolic parameters following targeted micronutritional supplementation. Methods: In this prospective, single-centre, open-label, single-arm pilot study, 15 adults with ultrasound-confirmed grade II–III hepatic steatosis and metabolic dysfunction received two micronutrient formulations for four months, without a new weight-loss programme. The prespecified primary efficacy target was a ≥10% reduction in mean Fatty Liver Index (FLI). Secondary outcomes included ultrasound steatosis severity, metabolic and biochemical parameters, quality of life, and safety. Results: The primary efficacy target was not achieved: mean FLI decreased from 59.18 to 56.63 (−4.3%; p = 0.256). Exploratory analyses showed a shift towards lower ultrasound-defined steatosis grades (nominal p = 0.010), with 13 of 15 participants improving and none worsening. Fasting glucose, insulin, homocysteine (−23%), and ferritin decreased, and transferrin saturation increased (nominal p ≤ 0.033), whereas BMI did not change. No serious adverse events occurred. Conclusions: Although the primary endpoint was not met, the exploratory within-participant changes in ultrasound-defined steatosis and selected cardiometabolic biomarkers warrant randomised controlled trials with quantitative hepatic fat assessment.